Title: Chemically modified tetracycline 3 prevents acute respiratory distress syndrome in a porcine model of sepsis + ischemia/reperfusion-induced lung injury.
Journal: Shock (Augusta, Ga.)20120401
Title: Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase.
Journal: Pharmacological research20111201
Title: Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS).
Journal: Pharmacological research20111201
Title: Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation.
Journal: Pharmacological research20111201
Title: Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.
Journal: Journal of neuro-oncology20111101
Title: A tetracycline analog improves acute respiratory distress syndrome survival in an ovine model.
Journal: The Annals of thoracic surgery20100801
Title: Matrix metalloproteinase inhibitors reduce collagen gel contraction and alpha-smooth muscle actin expression by periodontal ligament cells.
Journal: Journal of periodontal research20090401
Title: Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood.
Journal: Inflammation20090401
Title: Human laminin-332 degradation by Candida proteinases.
Journal: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology20080701
Title: A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.
Journal: Investigational new drugs20070801
Title: Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture.
Journal: Shock (Augusta, Ga.)20061201
Title: Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
Journal: Endocrine-related cancer20061201
Title: The immunoglobulin A1 proteinase from Streptococcus pneumoniae is inhibited by tetracycline compounds.
Journal: FEMS immunology and medical microbiology20061101
Title: In vitro inhibition of matrix metalloproteinase activity in tracheal epithelial lining fluid from horses with recurrent airway obstruction.
Journal: American journal of veterinary research20060701
Title: Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells.
Journal: International journal of cancer20060301
Title: Rob Ashley of AmpliMed discusses the discovery and development of Imexon. Interview by Steve Carney.
Journal: Drug discovery today20051015
Title: Chemically modified tetracyclines induce apoptosis in cultured mast cells.
Journal: International immunopharmacology20051001
Title: Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model.
Journal: Shock (Augusta, Ga.)20051001
Title: [Role of extracellular matrix degradation enzyme for glioma invasion].
Journal: Nihon rinsho. Japanese journal of clinical medicine20050901
Title: Effect of chemically modified tetracycline on transforming growth factor-beta1 and caspase-3 activation in liver of septic rats.
Journal: Critical care medicine20050701
Title: Tetracycline: from antibiotic to antisepsis.
Journal: Critical care medicine20050701
Title: Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]20050701
Title: Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Journal: International journal of cancer20050620
Title: A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection.
Journal: Journal of pharmaceutical and biomedical analysis20050401
Title: Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline.
Journal: Pharmaceutical research20050301
Title: Role of chemically modified tetracycline on TNF-alpha and mitogen-activated protein kinases in sepsis.
Journal: Shock (Augusta, Ga.)20041101
Title: A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20041001
Title: Transactivator mutants with altered effector specificity allow selective regulation of two genes by tetracycline variants.
Journal: Gene20040428
Title: Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid.
Journal: Journal of periodontal research20031201
Title: A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening.
Journal: The American journal of pathology20031001
Title: Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.
Journal: Journal of clinical pharmacology20031001
Title: Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis.
Journal: Shock (Augusta, Ga.)20030901
Title: Quantification of 6-deoxy-6-demethyl-4-dedimethylaminotetracycline (COL-3) in human plasma using liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20030825
Title: Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats.
Journal: The Journal of surgical research20030515
Title: Cleaning up the environment.
Journal: Drug discovery today20030201
Title: Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry.
Journal: Molecular cancer therapeutics20021101
Title: A chemically modified tetracycline (CMT-3) is a new antifungal agent.
Journal: Antimicrobial agents and chemotherapy20020501
Title: Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model.
Journal: International journal of cancer20020310
Title: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20020101
Title: Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives.
Journal: Journal of periodontology20020101
Title: Metalloproteinase inhibition prevents acute respiratory distress syndrome.
Journal: The Journal of surgical research20010801
Title: Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.
Journal: American journal of hematology20010501
Title: Drug-induced lupus associated with COL-3: report of 3 cases.
Journal: Archives of dermatology20010401
Title: Development of matrix metalloproteinase inhibitors in cancer therapy.
Journal: Journal of the National Cancer Institute20010207
Title: Biodistribution of radiolabeled [(3)H] CMT-3 in rats.
Journal: Current medicinal chemistry20010201
Title: CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer.
Journal: Current medicinal chemistry20010201
Title: Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3).
Journal: Current medicinal chemistry20010201
Title: Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity.
Journal: Current medicinal chemistry20010201
Title: Lee HM, et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMPactivity: relevance to cancer. Curr Med Chem. 2001 Feb;8(3):257-60.
Title: Liu Y, A chemically modified tetracycline (CMT-3) is a new antifungal agent. Antimicrob Agents Chemother. 2002 May;46(5):1447-54.
Title: Bildt MM, et al. CMT-3 inhibits orthodontic tooth displacement in the rat. Arch Oral Biol. 2007 Jun;52(6):571-8.
